Mon.Jun 05, 2023

article thumbnail

Artificial Intelligence & Antimicrobial Stewardship: An Interview With ChatGPT

IDStewardship

In this article the artificial intelligence program ChatGPT is interviewed about antimicrobial stewardship. Interview with: ChatGPT by OpenAI Interview by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article posted 6 June 2023 Antimicrobial resistance (AMR) has emerged as a global healthcare crisis, threatening our ability to effectively treat infections and safeguard public health.

Vaccines 246
article thumbnail

Why Choose a Career in Community Pharmacy?

Pharmacy Times

It’s imperative to redefine the future of pharmacy to help ensure a robust pipeline of future pharmacists and create a culture that helps ensure pharmacists live their purpose and passion.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Apple rolls out mental health tracking, vision assessment as new health app features

Fierce Healthcare

The roughly half of American smartphone users with iPhones will notice new health and pri | Apple brings its Health app to the iPad while offering new vision and mental health features to its suite of devices.

138
138
article thumbnail

Long-term Data Show Efficacy of Amivantamab-vmjw Combination for Patients With Mutated Advanced Non-Small Cell Lung Cancer

Pharmacy Times

In data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, amivantamab-vmjw plus lazertinib demonstrated promise as a first-line treatment for patients with advanced EGFR-mutated non-small cell lung cancer.

123
123
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Acute Cardiac Events Common During Hospitalization for COVID-19

Drug Topics

Patients were more likely to require ICU admission.

Hospitals 187
article thumbnail

FDA Approves First Intravenous Iron Replacement Therapy for Adults With Heart Failure, Iron Deficiency

Pharmacy Times

Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.

FDA 132

More Trending

article thumbnail

Clinical Overview: Steps to Implementation of Rebyota for Recurrent C difficile Infection

Pharmacy Times

Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.

122
122
article thumbnail

Younger people driving more high-cost claims for employers: survey

Fierce Healthcare

Self-insured employers face myriad challenges in trying to manage growing healthcare costs, and one of those results from recent history, according to a

Insurance 131
article thumbnail

Morning RX: June 5, 2023

Drug Topics

Mandy Cohen is set to become the next CDC director, Medicare will cover a new class of Alzheimer’s drugs, and the WHO announces a landmark digital health initiative.

98
article thumbnail

STAT+: Carbon Health is already using AI to write patient records

STAT

SAN FRANCISCO — Primary care tech startup Carbon Health is using artificial intelligence to listen in on patient appointments and automatically write up near-complete notes within minutes, directly in its own electronic health record software. Carbon — which has raised about $750 million in venture funding, including $100 million earlier this year — has been developing the AI-based health record software over the past few months and began using it on patients last month.

Hospitals 115
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Transcarent taps Andy Roddick's ViewFi for virtual orthopedic, MSK consults

Fierce Healthcare

Employee healthcare navigation company Transcarent has lined up its latest partnership, this time with digital health company ViewFi. | ViewFi is a virtual care platform built for orthopedic and musculoskeletal injuries and care. The company offers virtual healthcare, at-home exams and one-on-one appointments with orthopedic doctors and surgeons. Transcarent members will have access to some of the same orthopedic specialists that provide care to professional athletes.

113
113
article thumbnail

STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel

STAT

The Food and Drug Administration has removed a neurologist with financial ties to Biogen and Eisai — which jointly develop and market a pair of controversial Alzheimer’s drugs — from an upcoming advisory panel meeting to review one of those treatments. David Weisman was cleared two months ago by the agency as a temporary voting member of an advisory committee that will meet Friday to consider whether a drug called lecanemab, which is promoted by the companies, should be full

FDA 114
article thumbnail

Humana opens 250th primary care center as it continues to focus on growth

Fierce Healthcare

Humana's primary care arm opened its 250th clinic in Dallas on Tuesday, marking another milestone in the insurer's growth in the provider space. | Humana's primary care arm opened its 250th clinic in Dallas on Tuesday, marking another milestone in the insurer's growth in the provider space.

Insurance 113
article thumbnail

Cybersecurity in pharma: Securing the future

Pharmaceutical Technology

Earlier this year, Sun Pharmaceutical Industries , one of India’s largest generic drug producers, reported a major cybersecurity breach , impacting its business operations. A ransomware group later claimed responsibility for the incident, which was one of several high-profile cybersecurity breaches in India over the past three years. Pharma companies around the world have also faced similar threats , some of which have impacted national security and public health.

HIPAA 110
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Study Finds Association Between Vitamin D Levels, Obesity in Infertile Women

Pharmacy Times

Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.

123
123
article thumbnail

‘We arguably saved their lives’: Newborn DNA-sequencing reveals elevated cancer risks for parents

STAT

Ten years ago, clinicians in a handful of hospitals around the United States began sequencing the genomes of apparently healthy babies, seeking to understand how the technology might turn up hidden genetic disorders that aren’t being caught by routine newborn blood testing. New research from one such trial suggests the impact of having that kind of information extends far beyond the baby whose DNA is being decoded.

Hospitals 105
article thumbnail

Science Summarised: All Things Meningioma

NF2 BioSolutions

It’s NF2 science, but summarised! Visit the previous blog post in this series: Science Summarised: Potential New Drugs for Hearing Loss This blog was written by NF2 BioSolutions PhD student Grace Gregory. [Image Description] Grace Gregory in the laboratory at the University of Manchester. — People with NF2 -related schwannomatosis (known as NF2 and previously called Neurofibromatosis Type 2) can develop multiple tumour types, the most common being vestibular schwannoma that grow in t

article thumbnail

Akero’s NASH drug combined with Ozempic cut liver fat in small study

STAT

GLP-1s, a class of drugs including Ozempic and Wegovy that have become widely popular for treating obesity and diabetes, are also being studied for NASH , a form of fatty liver disease. But a new small study suggests GLP-1s may not dominate the disease area as they have others. Akero Therapeutics tested its experimental medicine efruxifermin in conjunction with a GLP-1, and found that patients taking the combination had reduced liver fat and improved markers of liver scarring compared with those

100
100
article thumbnail

BIO’s CEO digs into the hot-button issues facing the industry

PharmaVoice

Rachel King took the reins at BIO during a rocky time. Now, after steadying the ship, she’s brought the trade association’s focus back to the industry’s most pressing priorities.

98
article thumbnail

STAT+: How Blue Cross Blue Shield insurers ratcheted up profits in 2022

STAT

A $203 million tax refund for Blue Cross Blue Shield of North Carolina. Nearly $1.5 billion in profit for Health Care Service Corp., the parent of five Blues plans. A quadrupling of profit at BCBS of Alabama. Publicly traded health insurers were not the only ones in the industry that continued to amass large windfalls in 2022. Many nonprofit and private Blue Cross Blue Shield companies ended last year with sizable gains that added to their mountainous cash reserves, according to a STAT analysis

article thumbnail

AZ notches postmarket win for bleeding reversal agent Andexxa, plans to seek full approval

Fierce Pharma

After a postmarketing study of AstraZeneca's bleeding reversal agent Andexxa met its primary endpoint earlier than planned, AZ is ending the study at the recommendation of a data monitoring board.< | The phase 4 study ended ahead of schedule after it quickly established the benefits of Andexxa. AZ now plans to seek full approvals for the drug.

97
article thumbnail

For many who use power wheelchairs, CMS decision just made seat elevation much less expensive

STAT

This article is adapted from STAT’s latest report , Decoding Medicare: 10 key coverage decisions and how they’re made. F or years, patients and medical groups have advocated for Medicare to cover wheelchairs with power-seat elevation, allowing users to, among other things, reach cabinets and countertops more easily and conduct conversations eye to eye.

98
article thumbnail

Consumers notice rising retail crimes

Drug Store News

According to a survey conducted by the National Retail Federation, consumers believe retail crimes such as shoplifting and looting stores have increased in their community.

96
article thumbnail

STAT+: Bellerophon Therapeutics trial fails despite innovative digital endpoint

STAT

In an important reminder that plugging digital tools into a clinical trial will not magically solve problems, Bellerophon Therapeutics announced Monday it would abandon a study of its treatment for pulmonary fibrosis after patients in a Phase 3 trial using a digital endpoint showed no improvement. Bellerophon’s study, which the New Jersey-based company boasted was the first pivotal trial to use a Food and Drug Administration-endorsed endpoint using wearable data, was closely watched by la

94
article thumbnail

Medicare Still Won’t Pay for Alzheimer’s Drugs Without Confirmatory Data

PharmExec

Indicates that reimbursement for new slate of Alzheimer’s treatments will occur only with the completion of studies to support full approval.

105
105
article thumbnail

STAT+: Pharmalittle: AstraZeneca lung cancer drug halves death risk; 400 Grail patients incorrectly told they may have cancer

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin — in all sorts of directions. So to cope, we are, indeed, brewing cups of stimulation.

93
article thumbnail

Beauty shoppers turn to e-commerce for purchasing needs

Drug Store News

According to a new report from MikMak, when it comes to shopping for beauty product essentials, consumers are opting to purchase from e-commerce platforms.

98
article thumbnail

STAT+: Gilead’s CAR-T therapy prolongs survival in key blood cancer trial

STAT

CHICAGO — Yescarta, the CAR-T therapy made by the Kite unit of Gilead Sciences, prolonged the lives of patients with large B-cell lymphoma by 27% compared to standard treatment in a long-running clinical trial, researchers reported Monday. Proving a meaningful survival benefit for patients with a type of blood cancer represents another milestone for CAR-T therapy, which involves extracting white blood cells from a patient and genetically modifying them to attack cancer.

article thumbnail

FDA rejects Clovis' long-shot bid for approval of Rubraca

Fierce Pharma

Six months after filing for bankruptcy, Clovis Oncology was hoping for a last gasp | Six months after filing for bankruptcy, Clovis was hoping for a last gasp win for fading cancer drug Rubraca. But the FDA has rejected the company’s bid for approval of the PARP inhibitor as a first-line maintenance treatment for ovarian cancer patients who have responded to a round of chemotherapy.

FDA 90
article thumbnail

Opinion: How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra

STAT

Since a Texas judge’s decision dropped earlier this spring, Braidwood v. Becerra has sent shudders down public health’s spine. Similar to earlier contraceptive mandate cases, Braidwood involves plaintiff-employers who object to paying for health insurance that includes coverage of disease screenings and PrEP for HIV on moral grounds. Their legal claims challenge the U.S.

article thumbnail

Analysis reports nitrosamine prevalence in small molecule drugs

European Pharmaceutical Review

Based on an in silico analysis of over 12,000 small molecule drugs and drug impurities , a recent paper has reported that the presence of nitrosamines in pharmaceuticals is likely more prevalent than originally expected. In total, 40.4 percent of the analysed active pharmaceutical ingredients (APIs) and 29.6 percent of the API impurities were revealed as potential nitrosamine precursors.

article thumbnail

STAT+: FDA oncology head wants advisory panels to keep voting on new drugs

STAT

CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear he’d like to do away with the votes that punctuate meetings of expert panels evaluating new drugs for approval. On Sunday, Richard Pazdur, director of the FDA’s Oncology Center of Excellence, took issue with his boss. It’s true that the FDA has no obligation to follow what the advisory committee recommends, but the votes help, Pazdur said at STAT@ASCO, STAT’s event at th

FDA 91
article thumbnail

Consumers notice rising retail crimes

Drug Store News

According to a survey conducted by the National Retail Federation, consumers believe retail crimes have increased in their community.

105
105
article thumbnail

Study identifies key contamination source during ATMP manufacture

European Pharmaceutical Review

A two-year study monitoring microbial contamination of adipose tissue-derived stem cells (ADSC)-based advanced therapy medicinal products (ATMP) during manufacture , showed over 40 percent of lipoaspirate samples were contaminated with thirteen different microorganisms. over 40 percent of lipoaspirate samples [from ADSC-based ATMPs] were contaminated with thirteen different microorganisms” This is the first study to show this observation, according to the authors of the paper.